CD4+CD25+ T Regulatory Cells Dependent on ICOS Promote Regulation of Effector Cells in the Prediabetic Lesion by Herman, Ann E. et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2004/06/1479/11 $8.00
Volume 199, Number 11, June 7, 2004 1479–1489
http://www.jem.org/cgi/doi/10.1084/jem.20040179
 
1479
 
CD4
 
 
 
CD25
 
 
 
 T Regulatory Cells Dependent on ICOS 
Promote Regulation of Effector Cells in the Prediabetic Lesion
 
Ann E. Herman,
 
1
 
 Gordon J. Freeman,
 
3
 
 Diane Mathis,
 
1,2
 
 and Christophe Benoist
 
1,2
 
1
 
Section on Immunology and Immunogenetics, Joslin Diabetes Center, 
 
2
 
Department of Medicine, Brigham and 
Women’s Hospital, and 
 
3
 
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 
Boston, MA 02215
 
Abstract
 
CD4
 
 
 
CD25
 
 
 
 T regulatory cells (Tregs) prevent autoimmune disease, yet little is known about
precisely where they exert their influence naturally in a spontaneous autoimmune disorder.
Here, we report that Tregs and T effector cells (Teffs) coexist within the pancreatic lesion before
type 1 diabetes onset. We find that BDC2.5 T cell receptor transgenic animals contain a small
subset of FoxP3 positive CD4
 
 
 
CD25
 
 
 
CD69
 
 
 
 cells in the pancreas, actively turning over, ex-
pressing the clonotypic receptor, and containing functional regulatory activity. Gene expression
profiling confirms that the CD4
 
 
 
CD25
 
 
 
CD69
 
 
 
 cells in pancreatic tissue express transcripts
diagnostic of regulatory cells, but with significantly higher levels of interleukin 10 and inducible
costimulator (ICOS) than their lymph node counterparts. Blockade of ICOS rapidly converts
early insulitis to diabetes, which disrupts the balance of Teffs and Tregs and promotes a very
broad shift in the expression of the T regulatory–specific profile. Thus, CD4
 
 
 
CD25
 
 
 
69
 
 
 
Tregs operate directly in the autoimmune lesion and are dependent on ICOS to keep it in a
nondestructive state.
Key words: autoimmunity • diabetes • costimulation • tolerance • microarray
 
Introduction
 
Type 1 diabetes is an autoimmune disease that develops
when tolerance mechanisms fail to control immune responses
to pancreatic islet 
 
 
 
 cell proteins (1). Studies of autoimmune
diabetes are facilitated by mouse models, such as NOD
mice that develop diabetes spontaneously and TCR trans-
genic mice that express autoimmune TCR specificities
present within the natural NOD repertoire (1–8). Among
these, BDC2.5 TCR transgenic (BDC2.5) mice express a
TCR derived from a diabetogenic CD4
 
 
 
 T cell clone,
restricted by the MHC class II molecule A
 
g7
 
 (4, 9). Studies
of diabetes pathogenesis in both BDC2.5 and NOD mice
demonstrate that diabetes unfolds in stages (10). In BDC2.5
NOD mice, cells invade at 15–18 d of age and set up a
massive infiltrate inside the islet (insulitis; references 4, 11).
Yet, progression to diabetes occurs in only 10–20% of ani-
mals at 
 
 
 
20 wk of age. In most animals, the lesion settles
into a state of “respectful” insulitis, with the inflamma-
tory infiltrate clearly demarcated from functional 
 
 
 
 cells.
CTLA-4 blockade in BDC2.5/NOD or crossing to the
B6
 
H2-g7
 
 background results in a far more aggressive lesion
with 
 
 
 
 cell destruction and rapid diabetes onset (11–13).
What cellular mechanisms explain nondestructive insulitis
in BDC2.5/NOD? Either T cells entering the islets in
young mice are phenotypically incompetent to cause disease,
or they are actively prevented from doing so by a CTLA-4–
dependent immunoregulatory mechanism.
Immune regulation by CD4
 
 
 
CD25
 
 
 
 T regulatory cells
(Tregs) limits autoimmunity in several mouse models (14–16).
The FoxP3 transcription factor appears to play a unique
role as a master regulator of their phenotypic and functional
properties (17–19). In vivo, CD4
 
 
 
CD25
 
 
 
 Tregs depend
on mediators such as IL-10, TGF-
 
 
 
, and/or CTLA-4, but
their exact mechanism of action has not been fully eluci-
dated (20–25). Several studies of Tregs in transgenic models
have demonstrated that the cells expand in vitro and in
vivo to antigen presented by mature dendritic cells (26,
27), or in draining LNs of sites expressing cognate antigen
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(28–30). Transfer studies showed that CD4
 
 
 
CD25
 
 
 
 Tregs
home to the lamina propria and proliferate there during
regulation of induced colitis, although proliferation in this
system could not be separated from the lymphopenic state
of the host (30). Still at issue is the localization, proliferative
capacity, and function of Tregs in a spontaneous autoim-
mune disorder. Do the Tregs prevent the initial activation
of effector cells in the lymphoid organs, or do they act sec-
ondarily on effector cells in the target tissues?
Multiple lines of evidence suggest that CD4
 
 
 
CD25
 
 
 
Tregs are important in preventing responses in diabetes set-
tings. Depletion of CD25
 
 
 
 cells in a transfer setting or ge-
netic absence of CD28 (leading to low numbers of Tregs in
NOD mice) provoked exacerbation of disease (31, 32).
Administration of IL-10, vitamin D, or TNF-
 
 
 
 to NOD
mice promoted the generation of Tregs in conjunction
with amelioration of diabetes (33–35). Similarly, CD4
 
 
 
CD25
 
 
 
 Tregs may be reduced in the peripheral blood of
people with recent onset diabetes (36). Restoration of this
cell type may explain exciting recent advances in human
diabetes treatment. The generation of TGF-
 
 
 
–producing
Tregs by administration of anti-CD3 appears responsible
for the efficacy of this drug in early clinical trials (37, 38).
Thus, understanding the mechanism and point of action of
this important cell type may yield advances in human type
1 diabetes therapy.
Previous studies of regulatory cells in BDC2.5 mice de-
scribed clonotype
 
lo
 
 suppressor cells that came up in older
animals (39) or DX5
 
 
 
 populations effective in preinsulitic
mice (13). Here, we find that a defined CD4
 
 
 
CD25
 
 
 
 T
cell population with active regulatory properties can ac-
count for respectful insulitis in the prediabetes state in the
BDC2.5 mouse model of type 1 diabetes. Tregs coexist in
balance with aggressive effector cells directly in the autoim-
mune infiltrate, and express high levels of the immunoreg-
ulatory cytokine IL-10 in the pancreas compared with the
draining LN. Loss of this balance through blockade of the
costimulatory receptor inducible costimulator (ICOS) leads
to the rapid onset of diabetes.
 
Materials and Methods
 
Flow Cytometry. 
 
Single cell suspensions were prepared from
whole pancreas or indicated LNs using glass slide disruption. De-
bris was allowed to settle and removed (repeated two to three
times for pancreas). Staining with live cell dye was critical, espe-
cially with pancreas. We used either 7-AAD (BD Biosciences) or
Hoescht 33342 (CN Corp.). Cells were stained using standard
methodology with a combination of the following: B220-PE-
Texas red (RA3-6B2; Caltag), CD4-PE or PE-Cy7 (GK1.5),
ICOS-PE (7E.17G9), CD69-FITC (H1.2F3), CD25-allophyco-
cyanin (7D4 or PC61), or isotype controls rat IgG1 (R3-34) and
rat IgG2b (A95-1; BD Biosciences). Cells were analyzed on a
MoFlo
 
®
 
 flow cytometer using Summit
 
®
 
 software (DakoCytoma-
tion). Sorted cells were collected into media with 5% FBS and as-
sessed for purity (93–98% in transfer studies). For RNA prepara-
tion, cells were sorted twice to 
 
 
 
98% purity.
 
Mice and Transfer Experiments. 
 
BDC2.5/NOD mice were
maintained in the Joslin Diabetes Center barrier facility (IACUC
protocol 99-19, 99-20). Pancreata or total pooled LNs were iso-
lated from 3–4-wk-old BDC2.5 mice. Live B220
 
 
 
CD4
 
 
 
 cells
were sorted according to CD25/CD69 phenotypes and injected
i.p. into 4–12-wk-old NOD.scid recipients (The Jackson Labora-
tory). Diabetogenic BDC2.5 splenocytes were obtained from
6–10-wk-old mice. Mice were monitored for diabetes as de-
scribed previously (4).
 
Real-Time PCR Experiments. 
 
Total RNA was isolated from
sorted cells by standard TRIzol method from 10
 
4
 
 cells of each
group, and cDNA was prepared using Superscript II
 
®
 
 reverse
transcriptase (Invitrogen). cDNA from 1,250 cell equivalents was
used for real-time PCR for FoxP3 or IL-10 mRNA, using
HPRT as a standard. 2
 
-
 
  
 
CT
 
 calculations were used to present
amounts of expression relative to the whole LN control.
 
Gene Expression Profiling. 
 
Tregs (CD4
 
 
 
CD25
 
 
 
CD69
 
 
 
) and
T effector cells (Teffs; combined CD4
 
 
 
CD25
 
 
 
CD69
 
 
 
 and
CD4
 
 
 
CD25
 
lo
 
CD69
 
 
 
) were sorted from pancreas preparations to
 
 
 
98% purity as aforementioned. For ICOS blockade compari-
sons, mice were treated with two doses of anti-ICOS mAb or
control rat IgG as indicated. Cells were lysed in TRIzol, and total
RNA was prepared according to the manufacturer’s instructions
(Invitrogen). A method developed in-house was used to consis-
tently amplify RNA from small cell populations (Goldrath, A.,
personal communication). Amplification is primarily linear; addi-
tionally, any distortion of data is eliminated when samples ampli-
fied the same number of times are directly compared. This proce-
dure permitted analysis of transcripts from as few as 6,000 cells.
We performed three to five independent experiments for each cell
type. RNA was amplified for two rounds using the MessageAmp
 
®
 
aRNA kit according to manufacturer’s instructions (Ambion).
The last biotinylation step was performed using the Enzo Life Sci-
ences BioArray HighYield RNA Transcript Labeling Kit
 
®
 
 (T7).
5–15 
 
 
 
g of twice-amplified biotinylated aRNA was submitted to
the Joslin Genomics Core for hybridization to murine genome
U74Av2 array GeneChips
 
®
 
 as per the manufacturer’s instructions
(Affymetrix, Inc.). The raw data were processed with the RMA
algorithm for probe-level normalization (40), (S
 
 
 
 Array Analyzer;
Insightful; modified by R. Park [Joslin Diabetes Center, Boston,
MA], D. Mathis, and C. Benoist), and composite expression val-
ues were calculated for each of the genes on the chip (averaging
after outlier elimination; Distill software). Gene-wise p-values
were calculated with Welch’s modified Student’s 
 
t
 
 test and con-
verted to LOD scores as 
 
 
 
log
 
10
 
.
 
Antibody Treatments. 
 
ICOS-specific 7E.17G9.G1 (41) and
CTLA-4–specific UC10.4F10.11 (American Type Culture Col-
lection) mAbs were purified from hybridoma culture supernatant
by standard methods, either in-house or by Bio-Express or Har-
lan, and tested for endotoxin levels (
 
 
 
1.4 EU/mg protein). Each
lot was titered, and doses were set based on Ab equivalents by
flow cytometric activity (unpublished data). 7E.17G9.G1 mAb
was injected i.p. in two doses of 50–100 
 
 
 
g at 9 and 12 d, or
mice were injected with an equal amount of rat IgG2b isotype
control (A95-1; BD Biosciences), rat IgG (Sigma-Aldrich), or
PBS; or 400 
 
 
 
g of UC10.4F10.11 anti–CTLA-4 mAb as indi-
cated. For anti-ICOS treatment of older mice, two doses of 200–
400 
 
 
 
g 7E.17G9.G1 mAb were injected i.p. in PBS at 21 and
24 d, or starting at 26 or 35 d as indicated. In Fig. 6 A (right), an
equal volume of post-in-house mAb elution supernatant was used
as a control for endotoxin contamination (contains small amounts
of residual 17G9).
 
Online Supplemental Material. 
 
Specific genes identified by
GeneChip
 
®
 
 array data from pancreatic Tregs and Teffs are pre-
sented in Table SI. Datasets are available in the public Gene Ex- 
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pression Omnibus database (accession no. GSE1419). Online
supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20040179/DC1.
 
Results
 
The Pancreatic Lesion Includes CD4
 
 
 
 T Cell Subpopulations
with Both Effector and Regulatory Phenotypes.
 
Initially, we
asked whether cells in the prediabetes pancreatic lesion of
BDC2.5 mice (Fig. 1 A) are simply incompetent to cause
disease, or whether there is an active regulatory process oc-
curring in the islets. Preparation of islets followed by isola-
tion of lymphocytes proved detrimental to identifying all T
cells because heavily infiltrated islets fell apart during isola-
tion and were not included in the final yield. Therefore,
infiltrating T cells were prepared by mechanical disruption
of whole pancreata of young 3–4-wk-old BDC2.5/NOD
mice after careful removal of any LNs. The cells obtained
(routinely 3–5 
 
 
 
 10
 
6
 
 per BDC2.5/NOD pancreas) were a
true component of the infiltrate in that lymphocytes could
not be isolated from pancreata of strains with no islet infil-
tration (unpublished data). We divided the CD4
 
 
 
 popula-
tion into three subsets on the basis of the early activation
marker CD69 and the activation/regulatory marker CD25:
CD4
 
 
 
CD25
 
 
 
CD69
 
 
 
, CD4
 
 
 
CD25
 
lo
 
CD69
 
 
 
, and CD4
 
 
 
CD25
 
 
 
CD69
 
 
 
 (Fig. 1 B). Although CD4
 
 
 
 cells in the ir-
relevant inguinal LN (ILN) were mainly naive, those from
the pancreatic LN (PLN) or from the pancreatic lesion
were highly activated, with 15–40% of CD4
 
 
 
 cells display-
ing a CD25
 
lo
 
CD69
 
 
 
 profile consistent with recent activa-
tion. 3–11% of pancreatic infiltrating cells had a CD4
 
 
 
CD25
 
 
 
CD69
 
 
 
 phenotype, consistent with Tregs.
This phenotype suggested that the CD4
 
 
 
CD25
 
 
 
CD69
 
 
 
cells might contain the regulatory fraction, whereas those
CD69
 
 
 
 cells that were also CD25
 
 
 
 might reflect expres-
sion of the CD25 marker as a sign of recent activation. To
examine this issue, we sorted each cell type independently
from the pancreatic lesion, and assessed the expression of
the regulatory cell transcription factor FoxP3. Real-time
PCR analyses of the three populations indicated that
FoxP3 expression was highly enriched (10–35-fold in dif-
ferent experiments) in the CD4
 
 
 
CD25
 
 
 
CD69
 
 
 
 popula-
tion relative to the CD4
 
 
 
CD25
 
lo
 
CD69
 
 
 
 or CD4
 
 
 
CD25
 
 
 
CD69
 
 
 
 populations (Fig. 1 C), as in CD4
 
 
 
CD25
 
 
 
 cells
isolated from LNs. Even though the CD25
 
lo
 
CD69  cells
express some CD25, this did not reflect increased FoxP3
expression. CD69 appears to be a useful marker to sepa-
rate recently activated cells (which also express CD25)
away from CD25  cells expressing the regulatory tran-
scriptional controller FoxP3. A majority of the CD25 
CD69  cells (90%) expressed the clonotype receptor, as
Figure 1. Infiltrate in the pancreatic lesion contains subsets of CD4  cells with activated or regulatory phenotypes. (A) Islets of BDC2.5 mice at 4 wk
of age. (B) Cells from pancreatic infiltrate of 3–4-wk-old BDC2.5 mice were isolated as aforementioned and analyzed for CD4, B220, live cell dye,
CD25, and CD69 markers. Plots are gated on CD4 B220  live lymphocytes, and expression of activation markers CD25 and CD69 is shown. Data rep-
resent 10 separate experiments. (C) Pancreatic cells gated for CD4  expression, live lymphocytes, and B220  cells were sorted (whole CD4 ) or sorted
separately into the distinct CD25/CD69 subsets observed in B. Whole BDC2.5 LNs, or LN sorted into CD4 CD25  and CD4 CD25  subsets were
also prepared. cDNA was prepared from each indicated group and assessed for expression of FoxP3 cDNA by real-time PCR analysis. Data are presented
as relative expression of FoxP3 compared with the value in whole LNs (set to 1). Averaged results of three experiments are shown.
Figure 2. CD4 CD25 CD69 , CD25loCD69 , and CD25 CD69 
subsets are proliferating in the pancreas and LNs of unmanipulated BDC2.5
mice. 3–4-wk-old BDC2.5 mice were fed BrdU in their drinking water for
5 d. Pancreas (Panc), pancreatic LNs (PLN), or inguinal LN (ILN) were
isolated and analyzed by five-color flow cytometry for CD4, B220, CD25,
CD69, and BrdU expression. Cells were gated for lymphocytes,
CD4 B220  cells, and indicated CD25/CD69 subsets (as in Fig. 1 B). Iso-
type control (thick line) versus BrdU (thin line) staining is shown. Data are
representative of three experiments.Regulation within the Autoimmune Lesion 1482
did the other phenotypes (unpublished data). These data
suggest that a balance of putative Tregs and Teffs express-
ing the BDC2.5 receptor resides together directly in the
target organ.
Cells with Both Effector and Regulatory Phenotypes Are Ac-
tively Proliferating in the Pancreatic Lesion An interesting is-
sue was whether the T cells were actively proliferating in
the pancreatic lesion because previous analyses of Treg pro-
liferation have shown expansion in the draining node or in
the intestine of lymphopenic hosts (30), but not the target
tissue of autoimmunity in mice with a full lymphoid com-
partment. Flow cytometric analysis of mice fed with BrdU
for 5 d showed that all CD4  cell phenotypes in the pan-
creatic lesion proliferated (Fig. 2). If anything, CD25 
CD69  cells were the most active. This was also the case in
the draining PLN, but not in the irrelevant ILN. Thus, the
insulitic lesion is not inert, and cells with both regulatory
and effector phenotypes are turning over rapidly in the
presence of a full lymphoid compartment.
Functional Pathogenic and Regulatory Cells Coexist in the
Pancreatic Lesion. These data are suggestive of an active
balance of regulatory and pathogenic CD4  T cells in
the  pancreatic lesion. To evaluate function, we sorted
CD25 CD69 , CD25loCD69 , and CD25 CD69  cells
from BDC2.5/NOD pancreata were transferred into
NOD.scid recipients. Mice that received CD25 CD69 
cells or CD25loCD69  cells developed diabetes shortly af-
ter transfer (Fig. 3 A). As few as 10–20,000 cells of these
phenotypes were enough to provoke diabetes in 50–80% of
recipients within 1 mo after transfer. All mice that received
CD25 CD69  cells or CD25loCD69  cells, at the doses
tested, developed insulitis (unpublished data). In contrast,
CD25 CD69  cells did not cause diabetes or develop insu-
litis after transfer. We asked whether the CD25 CD69 
cells residing in the pancreas did, in fact, have protective
capacity by transferring 10–20,000 CD25 CD69  cells iso-
lated from the lesion with 5   105 diabetogenic BDC2.5/
NOD splenocytes into NOD.scid recipients. This small
dose of cells, 10–100-fold lower than the dose used in
other models of regulation using polyclonal populations
(20, 42), provided significant protection from diabetes in
this cotransfer context (Fig. 3 B). BDC2.5 LN Tregs
(CD4 CD25 CD69 ) were also effective at this dose (un-
published data). In vivo regulation was dose dependent be-
cause protection from diabetes was lost if only 5,000 Tregs
were cotransferred (Fig. 3 B). In protected mice that had
received 20,000 CD25 CD69  Tregs and 5   105 diabe-
togenic BDC2.5/NOD splenocytes, we observed formida-
ble, but respectful, insulitis in the islet after 30 d (Fig. 3 C),
similar to that seen in islets of unmanipulated BDC2.5/
NOD mice (compare with Fig. 1 A). Interestingly, Tregs
taken directly from the pancreatic lesion were unable to set
Figure 3. CD4 CD25 CD69  cells isolated directly from the pancre-
atic lesion protect from diabetes, whereas CD4 CD25loCD69  and
CD25 CD69  cells are pathogenic. (A) Cells from the pancreatic lesion
of 3–4-wk-old BDC2.5 mice were sorted into CD4 CD25 CD69 
( CD25 CD69 ), CD4 CD25loCD69  (  CD25loCD69 ), and
CD4 CD25 CD69 ( CD25 CD69 ) subsets by flow cytometry.
Sorted cells were transferred i.p. separately into NOD.scid recipients at
two doses as follows: 50,000 cells (closed symbols) or 10–20,000 cells
(open symbols). Mice were monitored every other day after 7 d for the
onset of hyperglycemia by urine, and diabetes was confirmed by blood
glucose levels  250 mg/dl. Data represent pooled results of three separate
experiments with similar results. (B) CD4 CD25 CD69  cells were
sorted as in A. Either 10–20,000 ( ), 5,000 ( ), or no ( )
CD4 CD25 CD69  cells were transferred i.p. into NOD.scid recipient
animals in combination with 5   105 diabetogenic BDC2.5 splenocytes.
Mice were monitored as described in A. Data represent pooled results of
three separate experiments with similar results. (C) Histological sections
were prepared from pancreata of transferred NOD.scid animals. Hema-
toxylin and eosin–stained sections from recipients that did not develop
diabetes (protected by Treg) by the end of 30 d after receiving the 10–
20,000 cell dose of CD4 CD25 CD69  cells and 5   105 diabetogenic
BDC2.5 splenocytes are shown.Herman et al. 1483
up a presence there in the absence of other T cells in the
NOD.SCID host, suggesting that they may require signals
from Teffs to access the pancreas or persist there. These
data demonstrate that Teff and Treg subsets coexist in the
pancreatic lesion, and that T effectors capable of disease
transfer are being actively suppressed by CD25 CD69 
Tregs during the nondestructive period of insulitis.
The Gene Expression Profile of Pancreatic Tissue Tregs Sub-
sets Is Distinct. To better understand the function and phe-
notype of effector and regulatory cells residing in the target
organ during autoimmunity, we compared the gene expres-
sion profiles of CD25 CD69  Tregs to the combined Teff
populations of CD25loCD69  and CD25 CD69  cells. We
sorted cells from the lesion, isolated RNA, prepared double
amplified biotinylated aRNA, and hybridized each sample to
an Affymetrix murine genome U74Av2 array GeneChip®
for at least three replicates of each population. A false posi-
tive rate (FPR) was estimated from a randomized dataset
generated by shuffling expression values between samples
(Fig. 4 A, randomized control). The CD25 CD69  Tregs
and Teff cell populations from the prediabetic lesion could
be distinguished by the expression of a limited set of genes;
with a 10% FPR cutoff, 96 genes were overexpressed in
CD25 CD69  cells, and 73 were underrepresented, signifi-
cantly more than in the randomized dataset (Fig. 4 A). Sev-
eral of the genes overexpressed in CD25 CD69  cells such
as GITR, CD103, Nrp-1, IL-10, and CTLA-4 are diagnos-
tic of Tregs with suppressive activity (Table SI, available
at http://www.jem.org/cgi/content/full/jem.20040179/
DC1; references 14–16, 43–46). Overall, this group was
dominated by cell surface or cytokine genes. Conversely, the
genes underrepresented in Tregs seemed dominated by tran-
scription or signaling factors (OBF-1, Tcf7, Eomesodermin,
and Smad1). We compared our data to 77 genes shown pre-
viously to be overrepresented in LN CD4 CD25  cells
from normal mice or from in vitro–activated cultures (45); as
illustrated in Fig. 4 B, many of these were also overrepre-
sented in pancreatic CD25 CD69  Tregs (21 out of 77
overlap with our list at 10% FPR; Table SI). However,
many of the genes on our list have not been identified previ-
ously as particularly expressed by Tregs. They might repre-
sent a unique subset of genes either induced in a subset of
Tregs to make them capable of accessing the tissues, or in
Tregs once within the lesion.
Tregs in Pancreatic Tissue Express Higher Levels of the Regu-
latory Cytokine IL-10, GITR, and ICOS than Those Found in
LNs. To compare more directly the differences between
Tregs found in tissue and their LN counterparts, we exam-
ined the expression of several regulatory molecules by flow
cytometry or real-time PCR. IL-10 is an important effec-
tor molecule for Tregs in several in vivo systems (for re-
view see references 14–16) and has been shown to be criti-
cal for regulation in the BDC2.5 model (47). We observed
that IL-10 was highly up-regulated in Treg in the pancre-
atic lesion compared with effector cells (Table SI). We
compared mRNA levels of IL-10 in Tregs isolated from
the pancreatic infiltrate or LN. Unlike FoxP3 levels, which
were similar between LNs and pancreatic Tregs (Fig. 1),
IL-10 levels were 15–36-fold higher in pancreatic Tregs
compared with those isolated from the PLN or irrelevant
mesenteric LN (MLN; Fig. 5 A). The GITR molecule was
also consistently present at somewhat higher levels on pan-
creatic versus LN Tregs (Fig. 5 B), as well as increasing on
activated cells in the pancreas. ICOS, a CD28 family mem-
ber, is known to be an important costimulatory receptor
for the production of IL-10 (48–51). Although ICOS is
usually thought to act as a positive costimulator, genetic
deficiency or Ab blockade of ICOS leads to exacerbation
of disease in mouse models of multiple sclerosis (48, 51).
ICOS was expressed on a small subpopulation (5–10%) of
CD25 CD69  Tregs in the LN, although interestingly
ICOS was always lower or absent on PLN Tregs (Fig. 5
Figure 4. CD4 CD25 CD69  cells have a gene expression profile of
Tregs, whereas CD25loCD69  and CD25 CD69  cells are distinct. (A) Cells
were sorted to high purity directly from the pancreas lesion of 3–4-wk-
old BDC2.5 mice for the CD4 CD25 CD69  population, or the
CD25loCD69  and CD25 CD69  combined populations. RNA was
prepared and hybridized to Affymetrix U74Av2 array GeneChips® as
described in Materials and Methods. RMA analysis was used to compare
relative expression of data from the CD4 CD25 CD69  population to
the CD25loCD69  and CD25 CD69  combined populations. The cut-
off for significant differences was determined using a random dataset to
identify a 10% FPR for the real data, in this case a 2.1-fold increase (or
decrease) in gene expression (highlighted in blue). For each cell type,
three to five separate experiments were performed. (B) The gene list of
77 from McHugh et al. (reference 45) is highlighted on our relative gene
expression graph in blue (up in LN CD25 ) and red (up in LN CD25 ).Regulation within the Autoimmune Lesion 1484
C). Strikingly, 30–80% of CD25 CD69  Tregs in the
pancreas expressed ICOS. Recently activated cells (CD25lo
CD69 ) showed no comparable ICOS expression. In some
experiments, ICOS was present on CD25loCD69  cells in
the pancreas (2–16%), but was of lower intensity. CD25 
CD69  cells did not express ICOS (unpublished data).
These data suggest that Tregs in the autoimmune lesion ac-
quire functional and phenotypic properties distinct from
their LN counterparts, in particular marked by high expres-
sion of ICOS. Higher levels of the regulatory cytokine
IL-10, GITR, and ICOS in Tregs specifically from the
pancreatic lesion suggest that Tregs function directly in the
target organ to mediate regulation.
ICOS Blockade Disrupts the Balance of Tregs and T Effectors
in the Lesion and Promotes Loss of Expression of Important Reg-
ulatory Molecules by Tregs. Abrogation of costimulatory
signals in both the NOD and BDC2.5 models has been
shown to lead to rapid onset of diabetes (32); in particular,
blockade of CTLA-4, known to be important for Treg
function, led to immediate onset of diabetes in young
BDC2.5/NOD mice if administered when they first exhib-
ited insulitis (11, 21, 22). To test if ICOS on Tregs in the
pancreas was important to maintain the balance of regula-
tion, we treated young BDC2.5/NOD mice with anti-
ICOS mAb. These animals developed diabetes rapidly at
the onset of insulitis, all becoming diabetic by 25 d of age
(Fig. 6 A, left). In contrast with the CTLA-4 blockade,
which is only effective when given before islet infiltration,
ICOS blockade could promote diabetes for a period after
insulitis onset as well (Fig. 6 A, right), although the effect
also waned in older animals.
We analyzed the frequency of CD4  CD25/CD69 T cell
subsets within the pancreas after ICOS blockade. ICOS
blockade led to an increased frequency of CD25loCD69 
Teff cells and a decreased frequency of CD25 CD69 
Tregs, resulting in a significant change in the ratio of the
two subpopulations (Fig. 6 B). This change only occurred in
the pancreatic infiltrate, but not in the PLN or irrelevant
LN, reflective of ICOS expression specifically in the pancre-
atic infiltrate. Anti-ICOS treatment did not lead to deletion
of Tregs because the absolute numbers of Tregs in the lesion
did not change; rather, an increase in Teff was responsible
for the skewing of the Teff/Treg ratio (unpublished data).
The blockade of ICOS perturbed the Teff/Treg ratio,
thereby disrupting the balance of regulation in the lesion.
Microarrays were used to analyze gene expression
changes induced by ICOS blockade in the two popula-
tions. Teff or Treg CD4  subsets were sorted as aforemen-
Figure 5. IL-10, GITR, and ICOS are specifically up-regulated in the
pancreatic lesion compared with the draining lymph node. (A) Cells were
sorted to high purity from the pancreas lesion, pancreatic LNs (PLN), or
mesenteric LNs (MLN) of 3–4-wk-old BDC2.5 mice for the
CD4 CD25 CD69 , CD25loCD69 , or CD25 CD69  populations.
mRNA was prepared from each indicated group and assessed for IL-10
expression by real-time PCR analysis. Data are presented as relative ex-
pression of IL-10 compared with the value in whole LNs (set to 1). The
average of three experiments is shown. (B) GITR expression (unshaded
histograms) was examined on CD4 B220  live lymphocytes gated on the
CD25/CD69 profiles indicated (Fig. 1 B) from the pancreas, PLN, or
MLN and compared with isotype control (shaded histograms). The data
shown are representative of three experiments. (C) ICOS expression (un-
shaded histograms) was examined on subsets as in B. The data shown are
representative of five experiments.Herman et al. 1485
tioned from 4-wk-old BDC2.5/NOD mice 5 d after treat-
ment with anti-ICOS or control rat IgG (Fig. 7 A), and
RNA probes were prepared for microarray analysis as
aforementioned. Changes induced by ICOS blockade were
more limited in the effector population than in Tregs; the
comparative plot was much tighter for Teff than for Tregs
(Fig. 7, B and C). In Teff, only 33 genes were induced by a
factor of  1.5-fold, and only 1 was repressed. Interestingly,
Figure 6. ICOS or CTLA-4
blockade in young BDC2.5 ani-
mals leads to rapid diabetes onset
and correlates with a disruption
of the T regulatory/T effector
balance. (A) BDC2.5 mice were
treated at 9 and 12 d of age with
anti–CTLA-4 or ICOS mAb,
indicated by arrow (left). Mice
were treated with two doses of
anti-ICOS mAb starting at 21,
26, or 35 d of age (arrows); with
anti–CTLA-4 mAb starting at
day 26; or with controls as de-
scribed in Materials and Methods
(right). Diabetes was monitored
as aforementioned. (B) BDC2.5
mice were treated at 21 and 24 d
with anti-ICOS mAb or control and killed at 26 d of age before diabetes onset. Pancreatic lesion, PLN, and ILN cells were prepared and stained with
anti-CD4, B220, CD25, CD69, and live cell dye. Percentages are shown of pancreatic CD4 CD25loCD69  cells (CD25loCD69 ) or CD4 CD25 CD69 
cells (CD25 CD69 ), gated on live lymphocytes and B220  cells (n   5; P   0.008, CD25loCD69  cells; P   0.008, CD25 CD69  cells by pairwise
Student’s t test). PLN and ILN are not shown because there were no significant differences.
Figure 7. ICOS blockade dampens the immunoregulatory gene profile and correlates with expression of proinflammatory cytokines. (A) Cells from
pancreatic infiltrate of 3–4-wk-old BDC2.5 mice were isolated after treatment with anti-ICOS mAb or rat IgG control as indicated, and analyzed for
CD25/CD69 expression profiles on CD4 B220  live lymphocytes. Data represent five separate experiments. Cells were sorted to high purity directly
from the pancreatic lesion of 3–4-wk-old BDC2.5 mice 5 d after indicated treatments for the CD4 CD25 CD69  Treg population, or the
CD25loCD69  and CD25 CD69  combined Teff populations. RNA was prepared and hybridized to Affymetrix U74Av2 array GeneChips®, and data
were analyzed as described in Materials and Methods and in Fig. 4. (B) Expression value comparison plot for Teff populations with anti-ICOS versus
control treatment. (C) Similar plot for Treg populations. (D) A ratio plot comparing the ratio of Treg anti-ICOS–treated/Teff anti-ICOS–treated profiles
to the same ratio in the Treg and Teff control-treated profiles. Diagonal line indicates where points would fall if nothing changed between the treat-
ments. A selection of genes that are highly over- or underexpressed after anti-ICOS treatment are highlighted. (E) Changes in expression values for
cytokines within the lesion in Treg and Teff cells from each treatment group are shown. Asterisks indicate fold changes  1.9.Regulation within the Autoimmune Lesion 1486
a number of these induced genes have also been found acti-
vated in a recent analysis of pancreatic destruction induced
by cyclophosphamide treatment of BDC2.5/NOD mice,
including IFN-  and several IFN- –regulated genes (Ma-
tos, M., personal communication).
In contrast, the changes affecting Tregs after ICOS block-
ade are far more profound, 215 and 21 genes were affected
at the 1.5-fold cutoff. The plot of Fig. 7 D is highly infor-
mative. First, it shows that essentially all genes that are un-
der- or overexpressed in control-treated Tregs compared
with control-treated Teff remain so after anti-ICOS admin-
istration. This provides an independent validation of the
“Treg signature” described in Fig. 4. Most importantly, it
also becomes clear that the differential expression of the en-
tire profile between Treg and Teff is lessened after ICOS
blockade, as evidenced by the off-diagonal shift. This “mut-
ing” of the Treg signature affects genes that are both over-
or underrepresented in Tregs (IL-10, GITR, and SOCS-2
or Tcf7, Eomesodermin, and Myb, respectively). It is as if
ICOS blockade induced a broad shift of gene expression
away from the Treg profile, toward one that is more similar
to other CD4  cells. We considered the caveat that the
CD25 CD69  cell population might be more contaminated
with effector cells after ICOS blockade, but ruled out this
possibility by simulating computationally what the Treg
gene expression values would look like given 5, 10, or 50%
contamination by the Teff population. Greater than 35%
contamination would be required for the shift seen in Fig. 7
D, an unlikely scenario given the decreased frequency yet
static absolute numbers of CD25 CD69  cells after ICOS
blockade (Fig. 6 B and not depicted), and given the similar
FACS® profiles with anti-ICOS or control treatment (Fig.
7 A). Another possible explanation is that a population of
CD25 ICOS FoxP3  cells is lost via antibody-induced cell
death, and replaced by a CD25 CD69  effector cell popula-
tion, thus keeping the numbers of cells with this phenotype
constant. However, ICOS  cells could still be detected at
similar frequencies after anti-ICOS treatment using labeled
anti–rat IgG (unpublished data), suggesting that there was no
large composition change within the CD25  population.
The two standout genes that were exceptions to the
down-modulation of the Treg profile were IFN-  and
Ccl-3 (MIP1 ). Paradoxically, these proinflammatory genes
were overrepresented in Tregs without treatment and fur-
ther induced by anti-ICOS in both Treg and Teff popula-
tions. Cytokines represented in the lesion switch from an
immunoregulatory to a proinflammatory profile (Fig. 7 E).
Thus, ICOS blockade induces changes in the relative num-
bers and in the broad gene expression profiles of the Treg
population, suggesting that ICOS engagement is necessary
to maintain the activity of the Treg populations in the le-
sion, and thus prevent   cell destruction.
Discussion
Several mouse models of autoimmune diabetes share the
feature of exhibiting a long quiescent period between the
initiation of insulitis and the onset of diabetes (10). Simi-
larly, the presence of islet-directed antibodies and T cells in
the blood of prediabetic individuals years before diagnosis
of diabetes suggests that the human disease might unfold in
these same stages (52, 53). In animal models, where it can
be assessed, the prediabetic state coincides with a local au-
toimmune infiltrate that refrains from terminal   cell de-
struction. This work aimed to unravel the localization as
well as cellular and molecular mechanisms that control
nondestructive insulitis, critical because this is likely to be
the stage at which many therapeutic interventions will be
attempted. We demonstrated the presence of both patho-
genic Teffs and active CD4 CD25  Tregs within the le-
sion of young prediabetic mice. Both were highly effective,
very few cells being required to effect full islet destruction
or, conversely, to exert full protection. The ability to rec-
reate a nondestructive lesion much like the one in unma-
nipulated young BDC2.5 or NOD mice by cotransferring
diabetogenic splenocytes and Tregs provides evidence that
locally acting Tregs are an important element in the estab-
lishment of nondestructive insulitis.
How do the tissue Tregs described here relate to previ-
ously described regulatory populations in the BDC2.5 sys-
tem? Kanagawa et al. (39) found that BDC2.5 clonotypelo
cells had regulatory properties, but these cells were not
CD25  and developed as the mice aged, thus likely repre-
sent a different regulatory population. Gonzalez et al. (13)
demonstrated that cells capable of protecting 10-d-old
BDC2.5/RAGo mice from fulminant diabetes were not
enriched in the CD25  fraction, but resided, at least in
part, in a population with markers, such as DX5, typical of
NK T cells. This population also promoted a state of “re-
spectful” insulitis, and had an effect directly in the islet le-
sion. The explanation for the divergence of these findings
from the current ones may reflect differences in timing be-
tween the two experimental systems as follows: the protec-
tive effect of the DX5  fraction required administration
before the onset of insulitis. One might speculate that these
cells are needed upstream of CD4 CD25  Tregs, perhaps
to promote their establishment.
We observed that both Teffs and Tregs were actively cy-
cling in pancreatic infiltrate. Similarly, Tregs could be ob-
served proliferating in LNs draining their specific antigen
site (28, 29), or in the lamina propria during regulation of
colitis in a lymphopenic environment (30). Together, these
observations clearly indicate that, in vivo, Tregs are not an-
ergic. Previous studies have suggested that antigen-specific
Tregs are not required for immunoregulation in TCR
transgenic models of multiple sclerosis, but are more effec-
tive than nonspecific cells (54, 55). Here, we found that
CD25 CD69  Tregs essentially all expressed the clono-
typic TCR, but although CD3 levels were equivalent to
clonotype levels, we could not rule out the presence of
dual TCR-expressing cells. The numbers of BDC2.5 Tregs
required for effective protection were 10–100-fold lower
than those needed in polyclonal cotransfer models of in-
flammatory bowel disease or autoimmune gastritis (20, 42).Herman et al. 1487
These data imply that TCR specificity of Tregs for antigens
in the target organ may be important for their effectiveness,
probably because it allows triggering of the cells at the ap-
propriate location.
The molecular mechanisms behind immunoregulation in
the lesion are partially revealed by the gene expression pro-
files of the cells residing there. Although there were similar-
ities to expression profiles reported for LN Tregs (45), some
of the genes overexpressed in CD25  Tregs are highly
evocative of local suppressive action. The chemokine recep-
tors CCR-2, CCR-5, and CXCR3 may control the entry
of cells into the site, especially given reported expression of
the cognate chemokines in the islets (56). CCR-2 has been
found recently to correlate with regulatory activity in a
model of autoimmune arthritis (57). Expression of mRNA
for the cytokine IL-10 was highly up-regulated in the pan-
creas compared with the LNs, which was consistent with its
antiinflammatory activity and its implication in Treg func-
tion in several studies (for review see references 14–16). In
BDC2.5 mice, IL-10 was observed to be protective and im-
portant for dominant regulation of diabetes in older animals
(47). The striking enhancement of IL-10 transcripts in the
pancreas suggests that regulation specifically occurs within
the target organ. Localization and increased production of
immunoregulatory molecules in the target tissue is likely
critical for preventing spontaneous autoimmunity from evolv-
ing into overt autoimmune disease.
This important balance of regulation is disrupted by the
loss of ICOS signals in the pancreatic lesion. Tregs are di-
luted out of the lesion and turn down the complete Treg
signature. Dependence on ICOS for expression of regula-
tory molecules such as IL-10 by other Treg types has been
shown in a model of airway hypersensitivity (58). Our
data demonstrate that ICOS is expressed on CD4 CD25 
Treg particularly in the target organ during autoimmunity.
There, it is essential for maintaining the Treg gene program
and, hence, preventing a switch to a proinflammatory envi-
ronment during the early phase of insulitis. Although we
cannot completely exclude that rather than dampening the
Treg gene profile, ICOS blockade somehow leads to an in-
crease in a CD25 CD69  effector population that contam-
inates the detection of CD25 CD69  Treg genes, cyto-
metric analysis shows no evidence that the CD25 CD69 
populations are significantly altered by ICOS blockade, nor
that ICOS blockade causes the loss of CD25 CD69 
ICOS  cells. It had been postulated that a Th1/Th2 switch
of effector cells was responsible for the exacerbation of au-
toimmunity after ICOS blockade in EAE models (48, 51).
The present data demonstrate that a loss of immunoregula-
tory capacity by CD4 CD25  Tregs is actually the mecha-
nism by which ICOS blockade functions early to exacer-
bate autoimmunity.
Understanding the molecular and cellular basis of immu-
noregulation in the lesion could lead to the development of
therapies that favor Tregs and promote long-term toler-
ance, even after an immune response has been well-estab-
lished in the islet lesion. Costimulatory receptor blockade
of ICOS upsets the balance of regulation directly in the le-
sion when it is first being established, and not in the drain-
ing node. It is interesting to consider what other signals
might provoke diabetes after establishment of nondestruc-
tive insulitis in mice or humans. Perhaps viral infections,
other environmental triggers, genetic factors, or age-
dependent waning of Treg efficacy observed in NOD mice
(31) disrupt the fragile balance of immunoregulation in the
lesion and provoke diabetes.
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